Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
暂无分享,去创建一个
R. Brentjens | L. Buie | Ryan J Daley | M. Hsu | S. Latcha | T. Purdon | J. H. Park | Brianne N Dixon | M. Hsu | Terence J. Purdon
[1] R. Pazdur,et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome , 2018, The oncologist.
[2] Daniel Li,et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.
[3] M. Geyer,et al. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. , 2016, Blood.
[4] T. Hew-Butler,et al. Incidence of Exercise-Associated Hyponatremia and Its Association With Nonosmotic Stimuli of Arginine Vasopressin in the GNW100s Ultra-endurance Marathon , 2015, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.
[5] A. Amin,et al. Current treatment practice and outcomes. Report of the hyponatremia registry , 2015, Kidney international.
[6] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[7] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[8] J. Herman,et al. Stress activation of IL-6 neurons in the hypothalamus. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[9] A. Nadjar,et al. Interleukin-6 activates arginine vasopressin neurons in the supraoptic nucleus during immune challenge in rats. , 2009, American journal of physiology. Endocrinology and metabolism.
[10] M. Moustaki,et al. Hypothalamic-Pituitary-Adrenal Axis and Interleukin-6 Activity in Children with Head Trauma and Syndrome of Inappropriate Secretion of Antidiuretic Hormone , 2003, Journal of pediatric endocrinology & metabolism : JPEM.
[11] R. Walker,et al. Cyclophosphamide induced hemorrhagic cystitis. , 1999, The Journal of urology.
[12] G. Chrousos,et al. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. , 1994, The Journal of clinical endocrinology and metabolism.
[13] T. Stillwell,et al. Cyclophosphamide‐induced hemorrhagic cystitis: A review of 100 patients , 1988, Cancer.
[14] V. Devita,et al. Clinical pharmacology of cyclophosphamide. , 1973, Cancer research.